Affect statin myopathy reduced form of coenzyme Q10?
Authors:
L. Zlatohlávek; R. Češka
Published in:
Kardiol Rev Int Med 2012, 14(4): 273-276
Category:
Overview
Background:
Statins significantly reduce CV morbidity and mortality. Unfortunately, one of the side effects of statins is myopathy, for which statins can not be administered in sufficient doses or administered at all.
Aim:
The aim of this study was to demonstrate the effect of coenzyme Q10 in patients with statin myopathy.
Methods:
28 patients (18 women and 10 men, aged 60.6 ± 10.7) were investigated and treated with different types of statins (atorvastatin, simvastatin, rosuvastatin, fluvastatin, pravastatin and lovastatin). Muscle weakness and pain were monitored using a scale of one to ten, on which patients expressed the degree of their problems. Examination of muscle problems was performed prior to administration of 60 mg per day reduced coenzyme Q10 and after 3 and 6 months of dosing. Statistical analysis was performed.
Results:
Pain decreased on average by 53.8% (p < 0.0001), muscle weakness by 44.4% (p < 0.0001). The Q10 levels were increased by more than 194% (from 0,903 μg/ml to 2.66 μg/ml; p < 0.0001).
Conclusion:
After a six-month administration of reduced form of coenzyme Q10, muscle pain and sensitivity statistically significantly decreased.
Keywords:
statin – statin myopathy – muscle pain – muscle weakness – reduced form of koenzym Q10
Sources
1. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781– 1790.
2. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–414.
3. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010; 12: 322–330.
4. Hubacek JA, Adamkova V, Zidkova K et al. Statin pharmacokinetics. Vnitr Lek 2008; 54: 62–67.
5. Schaars CF, Stalenhoef AF. Effect of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19: 553–557.
6. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401–408.
7. De Pinieux G, Chariot P, Ammi-Saïd M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333–337.
8. Mabuchi H, Nohara A, Kobayashi J et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195: e182–e189.
9. Young JM, Molyneux SL, Florkowski CM et al. Pharmacokinetic comparison of a generic coenzyme Q10 solubilizate and a formulation with soybean phytosterols. Phytother Res 2012; 26: 1092–1096.
10. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.
11. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681–1690.
12. Young JM, Florkowski CM, Molyneux SL et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100: 1400–1403.
13. Caso G, Kelly P, McNurlan MA et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409–1412.
14. Mabuchi H, Nohara A, Kobayashi J et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195: e182–189.
15. Laaksonen R, Jokelainen K, Laakso J et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851–854.
16. Laaksonen R, Jokelainen K, Sahi T et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57: 62–66.
17. Päivä H, Thelen KM, Van Coster R et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60–68.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2012 Issue 4
Most read in this issue
- Cardiorenal syndrome – from a nephrologist’s point of view
- Affect statin myopathy reduced form of coenzyme Q10?
- Cardiorenal syndrome with chronic heart failure – from a cardiologist‘s point of view
- Acute kidney failure and cardiovascular complication